Hoechst Digs Into Dade-Behring as Investors Dig Out?
Executive SummaryDade-Behring Inc. is buying back a portion of its outstanding stock, giving investors Bain Capital and Goldman-Sachs, which each own a third of Dade, some liquidity.
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.